Updates from SAC and Subcommittees

SCIENTIFIC ADVISORY COMMITTEE (SAC)

The ANZUP Scientific Advisory Committee (SAC) had hoped to meet face to face at the ASM in July. Of course that could not happen in 2020 and the July and November meetings proceeded by Zoom videoconference. The SAC is designed to be multidisciplinary, and one of its strengths (and challenges) is to bring together the expertise, experience, ideas, and creativity of its diverse membership. The SAC spends much less of its time reviewing the conduct of individual trials, and much more thinking about strategic development, scientific direction, improving processes, engagement of our members, and building productive external links. Our members are also key to ANZUP’s ability to communicate with its stakeholders and other groups with complementary interests to our own.

The SAC is informed and guided by input from its subcommittees: Bladder / Urothelial / Penile (BUP), Germ Cell, Prostate, Renal, Translational, and Quality of Life and Supportive Care. Membership of these committees is open to any interested ANZUP member. As the year has progressed and we have adjusted to life with COVID-19, our trials have continued to recruit. Below we provide an update on developments from the past two quarters, as well as current activity and any challenges and barriers we need to work to overcome. Highlights include: Current Trials BCG+MM • Recruitment is now approaching 300 patients of a planned 500. To assist with recruitment, we are aiming to open additional sites for the study, If you are not a member and wish to be, please let us know and we will add you. You can contribute at any level you like, ranging from active involvement in the committee functions and trial management / leadership, through to simple interest and receipt of the minutes. My hope is that every interested person feels that they are able and welcome to engage in these processes at whatever level you wish. These committees are the “engine room” of ANZUP and we want and need your ideas and energy.

Thanks as always to the members of the SAC, its subcommittees, the Consumer Advisory Panel, and the Board for its support.

IAN DAVIS Chair,

IAN DAVIS

BLADDER, UROTHELIAL AND PENILE CANCER (BUP)

Scientific Advisory Committee 11 | ANZUP UPdate Summer 2020

including Nottingham University Hospital in the UK which is part way through the site initiation process and is due to start recruiting patients very soon. This will mark the addition of the first international site to the study. Despite the current worldwide shortage of BCG, there have been no supply issues reported for BCG+MM at participating sites and MSD are opening a new BCG+MM supply centre to address global demand. Therefore, it is important that all ANZUP members remind centres that the best way to conserve BCG stocks in Australia is to continue recruiting patients to this study.

BUP (CONTINUED)

PCR-MIB

There are now 24 of a planned 30 patients enrolled on this study. The aim is to complete recruitment before a large randomised Phase III study is opened by MSD later this year/early 2021, to avoid competing with this study. Final analysis will occur once the last patient is recruited and completes 31 weeks of treatment. Members are encouraged to send appropriate patients to centres where they could be recruited to this study to help complete recruitment.

Below the Belt Funded Projects

Circulating immune cell changes in patients treated with Pembrolizumab and chemoradiation for bladder cancer (Weickhardt, 2016)

Tissue biomarkers have been collected at sites and will be transferred centrally in early 2021 for analysis. As yet, translational work on blood biomarkers has not begun. This will occur following completion of accrual of samples.

ACCEPT ANZUP Co-operative multi-centre cystectomy database (Hayne, 2017)

An abstract on 100 consecutive patients was presented at the ANZUP Mini ASM. St George Hospital and Nepean Hospital have recently received approvals and joined the project as participating sites. Eastern Health and Royal Melbourne Hospital are also close to opening. PIs at other sites will be contacted in the near future to seek an update on progress with opening the study.

EXERCYST: Exercise Medicine Prior to Open Radical Cystectomy: Feasibility and Preliminary Efficacy (Taaffe, 2017)

A total of 17 of a planned 20 patients have now been recruited. Exercyst 2 trial is now under development for immediate post-operative exercise. Trials in Development

WAter or Chemotherapy to prevent Urothelial carcinoma a pre-imPlantation (WACUP) (Sengupta)

There are now 25 out of 30 patients recruited to this study. A grant application for the phase 3 larger study has beensubmitted in Q4 2020. Thank you to our Urology members who provided information via survey to help support this application. The phase 3 Randomised trial has been submitted for funding under the new title: WATER Trial- Water irrigation versus intravesical chemotherapy After Trans-urEthral resection of low grade urothelial cancer of the bladder.

SUBDUE-1: SUB-urothelial Durvalumab InjEction-1 (Hayne)

A protocol paper has been submitted. Four patients have been recruited. The dose of durvalumab has been escalated and no major immune-related safety issues have been reported.

Concept Submissions

The Concept Development Workshops give members a unique opportunity to present new concepts, participate in lively discussion around gaps in research, and plan for future grant applications. ANZUP remains committed to supporting our membership while continuing to promote and encourage members to bring new concepts forward to ensure protocol development. We encourage all members of the BUP Subcommittee to bring new concepts to the next Concept Development Workshop.

We would like to thank all BUP members for their commitment during this challenging year. We hope 2021 allows BUP concepts and trials to progress unimpeded so we can look forward to a productive year.

DICKON HAYNE & SHOMIK SENGUPTA Chair and Deputy Chair, BUP Subcommittee

QUALITY OF LIFE AND SUPPORTIVE CARE

And that was 2020 – it literally zoomed by.

In a time of global upheaval it is quite staggering to realise it was business almost as usual for ANZUP. Given we were already avid users of tele- and videoconferencing, it was a relatively smooth transition to Zoom for concept development workshops which meant work could continue. And how wonderful was it to be able to proceed with the mini-ASM in November, with some hubs enabling small groups to be together for the meeting. I wanted to acknowledge our Victorian ANZUP family who were so amazing in coping with a very tough lockdown situation. I hope you all have plans to enjoy the freedom you worked so hard to earn. I for one am looking forward to a break from looking at little boxes of people on the screen.

Concept Development Workshops

In October, we held another concept development workshop. It was inspiring to have five new concepts presented to the group, many in very early stages of development which allowed the authors to gain maximum input from the collective wisdom of the group.

We were excited to hear about Catherine Paterson’s proposed mixed methods study of the unmet needs and quality of life of men diagnosed with penile cancer. This is a rare cancer, with apparently significant impacts on many, many aspects of men’s lives. The study has the potential to provide major insights into how we can better support men affected by this cancer. It will be a world first, and help ANZUP to establish networks with the clinicians treating penile cancers at the moment.

Felicia Roncolato presented her concept proposing a phase II trial of oxybutynin for troublesome hot flushes in men on ADT for prostate cancer. We are currently working on a proposal to access the data from existing, completed trial to explore the symptom clusters associate with hot flushes. This will be a big step forward in understanding how we might effectively intervene to reduce these symptoms in men. Lorna Pembroke discussed her PhD study, PROCOG, investigating the cognitive impact of prostate cancer and treatments. Lorna’s study had previously been considered by the prostate cancer subcommittee and has subsequently been granted endorsement by ANZUP. I know Lorna is seeking people who are willing to refer men to the study for a one-off assessment which can be done via phone or videoconference.

Jasmine Yee sought input on a proposal investigating the feasibility and usefulness of body composition measurement with a bioimpedence device. One of the things needing exploration in this context is whether the reports provided can be used to facilitate engagement with lifestyle interventions such as exercise programs.

Noel Castan QOL Fellowship

As you will all be aware, Kath Schubach (Nurse Practitioner) was awarded the Noel Castan Fellowship during 2019. Kath has decided to focus her work on the quality of life amongst people with bladder cancer. It is exciting she now has agreement from the BCG + Mitomycin C trial management committee to use the HQOL data from stage 1 of the trial to describe the quality of life of patients over time. This will be the first step in understanding how the disease, treatments, follow-up, and recovery impact the quality of patients’ lives. Kath is well supported in her Fellowship by our Deputy Chair, Prof. Catherine Paterson.

Subcommittee Meetings

During 2020 we have held regular subcommittee meetings and while many of our members are focused on completing their BTB Pedalthon grants, we are seeing increased input into ANZUP trials more generally. This input is increasing the range of psychosocial and supportive care questions being addressed within the trials, aiming to better understand how we can support patients throughout their treatments and beyond.

ASM 2021

As you are all aware, it was necessary for ANZUP to postpone the ASM due to the COVID-19 restrictions. We were delighted to have Cristiane Decat Bergerot join us for the mini-ASM as part of one of the ANZUP in Conversation sessions. Her insights regarding the patient experience, decision-making, and coping with GU cancers and their treatments were refreshing and provided a lot to think about. We are so pleased, that all things going well, Cris will join us as an international speaker for the ASM in Adelaide in July. 13 | ANZUP UPdate Summer 2020

QUALITY OF LIFE AND SUPPORTIVE CARE (CONTINUED)

Future psychosocial and supportive care researchers?

While several of our members have welcomed new babies into their families this year (congratulations Camille Short on the safe arrival of Sascha and congratulations to Ben Smith on doubling output with the arrival of Edward), it will take some time before they may decide on a preference for quality of life and supportive care. So, we are doing our best to identify people with an interest in the area to be nurtured and supported as they develop research skills in this space. We also have several ideas suitable to be taken We would like to thank ANZUP as well as the investigators and trial teams for their continued efforts throughout a difficult and turbulent 2020. Below is an update of renal cell trials and other ongoing activity and developments. treatment. An abstract has been accepted for ASCO GU 2021 for the preliminary results of Part 1. A translational research plan is being drafted that will be presented to the Translational Research Committee for review. A BIG THANK YOU to all the patients, their families, clinical trial coordinators and investigators involved in this trial and the BaCT team for coordination and data analysis. An analysis of the tumour response by RECIST in UNISoN was presented at the ANZUP mini ASM by Deepti Pandey, showing the challenges involved, and winning the best Coordinator talk at the meeting. but surely. We would like to thank all the KEYPAD investigators and trial teams for their continued efforts throughout a difficult and turbulent 2020. So far KEYPAD has recruited a total of 42 patients out of a total of 70 patients. The concept of inhibiting tumour associated macrophages with denosumab is increasingly relevant with many other studies testing this idea internationally. Please continue to promote the up by fellows and/or trainees, this would be win-win in engaging their interest and getting some of our projects completed. Please do get in touch if you have people you know who would be interested.

Wishing you all a safe, restful, and uneventful few weeks over the summer holidays.

HARYANA DHILLON & CATHERINE PATERSON Chair and Deputy Chair, QoL and Supportive Care

RENAL CELL CANCER

Subcommittee KeyPAD trial and encourage cross-referral for suitable patients to support this important hypothesis.

The UNICAB study is open across 11 sites in Australia

The UNISoN study has the last few participants on

The KeyPAD study continues to recruit, slowly and has recruited 17 of 48 patients to date. We are excited that ANZUP’s first tele-trial site for UNICAB at Goulburn Valley Health in Shepparton has launched.

After many years of development, the RAMPART study is open and recruiting in the UK, and ANZUP hopes to clear the remaining logistical hurdles to be able to open this trial here in Australia. People with large/ higher risk primary kidney cancers may be eligible to take immunotherapy monotherapy or combination versus observation. There are more steps to take but we hope to open the study in early 2021.

We’ve proposed a novel platform trying to test new ideas to run clinical trials in the CELEBRITY project. Funding applications have been submitted but this remains in early stages of development. The idea is to make a clinical trial platform embedded in routine clinical practice using pre-existing resources. A number of emerging solutions will be tested, to see if these methods and technologies will enable us to share clinical trials to more Australians with kidney cancer. The aim is to capture data for outcomes of most

RENAL CELL CANCER (CONTINUED)

interest (e.g. survival), provide a platform for smaller sites to take part in ANZUP trials, and ultimately reduce workload for sites and improve patient outcomes. Further grant applications are being prepared and we hope to be able to develop and launch this project soon.

We’d like to recognise and congratulate again Assoc Prof Andrew Weickhardt for the Below the Belt Research Fund grant: 68Ga-PSMA PET as a potential Imaging biomarker post tyrosine kinase inhibition of metastatic clear cell Renal Cell Cancer (PIRC) – a pilot study.

Many targeted therapies affect cancer blood vessel development, and this project seeks to understand whether a PSMA PET scan is useful in visualising patients’ tumours after they have been treated with these therapies.

Additionally, this study will endeavour to understand if tumours that remain active on PSMA PET might be sensitive to another tablet targeted therapy, potentially allowing us to tailor the right treatment, to the right patient, at the right time. We extend our thanks to subcommittee members who have referred new members to support membership growth. We encourage continued referral of new members - varying disciplines, trainees and different geographical locations - are all welcome. ANZUP is planning a RCC Horizon scanning meeting for February 2021, where we hope to examine the current data, the gaps and the opportunities for ANZUP to lead to future developments. The RCC Subcommittee will also hold a Concept Development Workshop a few weeks later in April 2021. We encourage all RCC Subcommittee members, as well as our emerging researchers, trainees and recent graduate members, to attend and present a concept. The workshops continue to provide opportunities to brainstorm potential answers to tough clinical questions in kidney cancer research, as well as the development of paths towards fully-fledged kidney cancer trials. You can find ANZUP’s concept development template on the secure section of the ANZUP website.

We look forward to 2021 when we can further progress renal cell trials and concepts. We have learned this year that we as a global community can work together to solve challenging health problems. We look forward to continuing to work to the goals of preventing, treating and curing kidney cancer in partnership with our patients.

CRAIG GEDYE & DAVID POOK

Chair and Deputy Chair, Renal Cell Subcommittee

CRAIG GEDYE DAVID POOK

Find out more about ANZUP’s Concept Development Workshops and download the Concept Template

PROSTATE CANCER

After several years of sterling service chairing the ANZUP prostate subcommittee, Scott Williams has moved on to take on the Deputy Chair position on the SAC. On behalf of the ANZUP membership, we would like to acknowledge Scott’s leadership, and look forward to his ongoing contributions to the prostate powerhouse.

We convened our first subcommittee Zoom under the new regimen of Lisa Horvath and Jarad Martin, and had the usual animated and wide-ranging discussions over the relevant aspects of the ANZUP trial portfolio. Lisa won much acclaim for somehow keeping the discussions contained to under one hour.

DASL-HiCaP

DASL HiCaP has hit the ground running, with 89 men already randomised, and new sites coming on line at an impressive pace. Anecdotally, the majority of men are being managed in the De Novo setting, and we would remind clinicians that the trial is also open to men experiencing high risk relapse within a year of prostatectomy.

Lu-PSMA Studies

Where TheraP led, several others are hot on the heels. ENZA-p is now open for the metastatic Castrate Resistant group, with 13 men already recruited. The ANZUP co-badged UpFront PSMA is available for Castrate Sensitive men with high volume metastatic disease at diagnosis, with 6 randomised.

New Concepts The lifeblood of ANZUP is the pipeline of new trial concepts which are originally presented at a concept development workshop, and then progressed through individual working parties with updates to the prostate subcommittee. Several evolving concepts were discussed including Primary 2 looking at the integration of PSMA PET and mpmMRI in the original diagnosis of prostate cancer with the aim of risk adapting diagnostic biopsy. In the post-operative salvage setting, two concepts are taking shape. DIPPER is looking at a mixture of treatment de-intensification for the low risk patient group, and integration of PSMA PET into treatment planning for other men. The co-badged CHyPPR is exploring a shorter salvage radiotherapy schedule given over 4 weeks rather than the standard 6-7 week approach, potentially as a registry randomised trial. STAMPEDE-Oligo discussions between ANZUP and the UK are ongoing, particularly regarding the integration of DNA damage testing and integration of PARP inhibition.

Translational Substudies

The ENZAMET trial is proving to be a gold mine for translational research, with planned studies in genomics, cytokines and lipidomics planned for 2021. An engaged translational group is meeting regularly, and welcomes broader engagement. Other completed trials such as TheraP are also a great reservoir of potential translational sub-studies, and any interested investigators are encouraged to contact the relevant study principle investigator to discuss.

Changing practice for the benefit of our patients is the guiding principle for ANZUP. We had an update that based on the findings of ProPSMA, there has been significant progress potential MBS funding of this disruptive technology in 2021. We look forward to continuing this tradition of success, and strengthening ANZUPs reputation as the world’s premier collaborative trials group for genitourinary cancers.

LISA HORVATH & JARAD MARTIN

Chair and Deputy Chair, Prostate Subcommittee

GERM CELL CANCER

The second half of the year has again been very productive with a subcommittee meeting and a concept development workshop recently held. Our focus was to get a surgical study underway and receive funding for a stage 1 study looking at microRNA and fear of cancer recurrence. Below you can read if this occurred.

Ongoing activity in the Germ Cell Subcommittee include:

1. TIGER is now open at 4 sites in Australia, with recruitment at 9 patients. This study aims to demonstrate how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumours that have returned after a period of improvement or did not respond to treatment.

The open-label, randomised, stratified, 2-arm, multicentre phase 3 trial, led by Dr Darren Feldman from MSKCC, aims to recruit 420 patients internationally, with 60 patients to be recruited from Australia and New Zealand. Members are encouraged to refer relapsed patients to TIGER where possible.

2. iTestis is continuing to expand, opening at multiple sites across the country, with data for over 300 patients on the database. This is a testicular cancer registry, supported by ANZUP, that hopes to engage as many sites and clinicians as possible. Please contact Ben Tran if you are interested in participating. Data collection support can be provided.

3. P3BEP has continued to recruit well despite the challenging circumstances. 144 patients have now been recruited across ANZ, UK and COG sites. Blood and tissue from consenting P3BEP participants will be collected for translational research studies. Members are reminded to consider the study for their patients either at their site or at others where the trial was open.

4. The ANZUP surveillance guidelines for both stage 1 and advanced disease (following curative chemotherapy) are now available on the ANZUP website and are pending eviQ review. Please contact Ben Tran if you are interested in leading the development of a Stage 2 seminoma surveillance protocol.

5. Liz Connolly recently presented “A Review of the Australian Experience of High Dose Chemotherapy and Stem Cell Transplants for Germ Cell Tumour” at MOGA and again at the ANZUP ASM. This is fantastic local data demonstrating the excellent survival in Australian germ cell tumour patients who have received high dose chemotherapy for refractory disease.

In the pipeline, the following continue to be a focus for the Germ Cell Subcommittee for 2021.

1. Micro RNA analyses appear to be a promising biomarker for testicular cancer, both seminoma and non-seminoma. The CLIMATE study has been designed through the concept development workshop, and will have sufficient funding to start in 2021. The aim will be to recruit ~200 patients with stage 1 testicular cancer over 2-3 years from 7-8 sites and correlating miR-371 with recurrences.

2. The use of primary RPLND in stage 2A/B seminoma and marker negative non-seminoma is gaining momentum. The PRESTIGE protocol examining the changes in HRQoL in patients undergoing primary RPLND is being circulated and we aim to open this study in 2021 as well.

The Germ Cell Concept Development workshop was held on 13 November and resulted in a lot of productive discussion. The concepts presented included: • PRESTIGE- Primary RPLND Study Primary retroperitoneal lymph node dissectipn (RPLND) for clinical stage II (CSII) testicular germ cell tumour (TGCT) • CLIMATE- miR 371 cohort study • National audit results of high-dose chemo/ASCT • Chemo/Cog Data Analysis • Nationwide Tumour Board for Testis Cancer • Hypogonadism Study

Hopefully next year we are not faced with as many challenges and are able to progress some of the studies that are in the pipeline as well as some of the concepts above. We encourage you to join our subcommittee meetings and the concept development workshops. Here’s to a busy, productive 2021 – hopefully with a few face to face meetings!

BEN TRAN & FRITHA HANNING Chair and Deputy Chair, Germ Cell Subcommittee

TRANSLATIONAL RESEARCH

The past two quarters, since the last update, has seen another busy period. In addition, the first Translational Research Subcommittee (TRS) meeting was held. This led to a lot of robust discussion. Below are noteworthy updates and next steps.

ANZUP aims to make translational research a key focus and strength of the organisation moving forward. Therefore the TRS will facilitate overall translational research activity for ANZUP-led trials. We encourage any ANZUP members who are actively involved in translational research to not miss the opportunity to be part of this subcommittee.

Translational research plans are in place for ANZUP prostate cancer studies. For the non-prostate cancer trials more work is currently required to form a translational research plan. In addition, international trials e.g. ENZAMET and ENZARAD, have established a Translational Research Trial Executive Committee (TEC), which includes representation from the regions, and will not come under the direct responsibility of the TRS.

Results from the TheraP trial have established 177 Lu-PSMA as a new standard of care option in metastatic castration-resistant prostate cancer (mCRPC). Funded by PCFA, TheraP demonstrated that Lu-PSMA had superior PSA response rates (PSA RR) and PSA-progression-free survival (PSA-PFS) compared to cabazitaxel. Despite these practice-shaping results, outcomes from Lu-PSMA are variable and identifying molecular predictors is a priority.

We will shortly commence planning for correlative samples collected for TheraP. By testing circulating biomarkers in pre-treatment blood samples collected on TheraP, we hope to better understand why some men respond and others do not benefit from Lu-PSMA therapy. This will help us to better use this new agent and result in improved outcomes for men with advanced prostate cancer. Results from this world-first study will be presented at ASCO GU 2021. ANZUP holds face-to-face Concept Development Workshops (CDWs) to promote and encourage members to bring new concepts forward for development. The CDWs are designed to facilitate and support members who actively contribute in teleconferences and across research activities and have an idea/concept they would like to put forward for discussion. And if supported, this concept could further develop into a future grant application.

At present the TRS is considering an initial Concept Development Workshop be held as an educational event. If you are interested in topics such as single cell/ whole genome sequencing and analysis, as well as discussion about opportunities for collaboration, please let us know.

As always, we are grateful for the patients and families who enrol on our trials and donate bio-specimens that support our translational research. We could not conduct our activities without these high-quality samples. We would also like to acknowledge the participating sites thoroughness in obtaining correlative samples from our ANZUP trials. Bio-specimen collection continues as part of existing trials, including ENZA-p and DASL-HiCaP, BCG+MM, P3BEP, KEYPAD, UNISoN and PCR-MIB.

All ANZUP members are reminded you are welcome to participate in any of the subcommittees at whatever level you wish. If you would like to join the Translational Research Subcommittee please let the ANZUP secretariat know so you can be added.

We look forward to a productive 2021 for the Translational Subcommittee and continued translational research activity for ANZUP.

ARUN AZAD & ANTHONY JOSHUA Chair and Deputy Chair, Translational Subcommittee

CONSUMER ADVISORY PANEL (CAP)

As 2020 draws to a close it will certainly be a year that we remember, especially for the Melbourne CAP members who were locked down for months! As hard as it was at the time, we are extremely grateful we have all remained COVID healthy. On a global scale, being in Australia/NZ seems the best place to be and we are now looking forward to enjoying the warmer months ahead, spending time with family and friends, albeit still with some restrictions.

The CAP had its last meeting for the year in early November and 2 additional guest presentations were added to the agenda.

Lorna Huang presented her concept ‘Characterising prostate cancer patients undergoing hormone therapy: Is there a group of men more at risk of cognitive changes? A cross-sectional study.’ Lorna was seeking feedback from the CAP regarding the patient surveys that underpin the study and to consider how recruitment to the study could be improved.

Lucy Byers, ANZUP Marketing and Communications Manager, also presented a summary of the recently completed and successful #YourWay campaign. It was great to see that all of the CAP contributed to this event in some way through participation, fundraising, donating and promotion. We hope to see this event continue in the future.

Despite a slower start to the year and missing our annual face to face education session and ASM, we have just spent the last couple of days attending the Virtual Mini ASM #ANZUP2020. This was a fabulous way to finish off the year COVID style and included many excellent presentations. Well done to our CAP member Melissa Le Mesurier who co-chaired the ANZUP Symposium and a special thanks to Scott Williams and Dickon Hayne for acknowledging the commitment and work the CAP willingly does to support ANZUP’s research activities from a consumer perspective. We are looking forward to the ASM 2021 in Adelaide. The CAP was also involved as a team in reviewing the research applications received for the Below the Belt Research funding grants. A new review process was put in place following feedback from CAP member Colin O’Brien to ANZUP. Draft CAP grant review guidelines were hastily written. These guidelines will be finalised in the New Year. With these guidelines the CAP then reviewed and discussed the applications, and provided our rankings. These were then collated and very closely matched the rankings of the other panel members. This gives the CAP confidence that our ranking is the voice of the community rather than as an individual.

Patient Information and Consent Form Reviews (PICF) were recently completed by the CAP for:

ZipUp

The CAP believes the trial protocol is straight forward. We are also of the opinion that if we were in the same position as the cohort of patients being invited to participate in this study, we would all be agreeable to put ourselves forward. Improving scanning techniques for staging purposes to ensure the most appropriate treatment for patients was considered very important by the CAP.

UNICAB Master Teletrial PICF

The CAP reviewed the original UNICAB PICF back in 2018 (not then recruiting as a teletrial). This PICF had been adapted for use in a teletrial model that has been developed rapidly to deal with COVID-19 restrictions and social distancing. It is very pleasing from a community point of view, that despite the terrible effects COVID-19 has had more broadly, it has certainly sped up the process for developing the teletrial models. This hopefully results in much better access for trials, especially for those living in regional and rural areas.

CAP members have attended the recent concept development workshops, disease specific subcommittees and continue to provide articles for ANZUP‘s consumer magazine and UPdate newsletter. CAP member Melissa Le Mesurier attended her first Fundraising and Promotions (Partnership) Subcommittee meeting after her recent appointment and Leonie Young and Ray Allen, other CAP members, were nominated to attend the Translational Research

Subcommittee to offer CAP representation.

CAP (CONTINUED)

ACTA Trial of the Year Awards – Consumer Involvement Award

I was delighted to be able to accept the Consumer Involvement Award on behalf of ANZUP and the CAP. The ENZAMET trial was one of the first PICF’s the CAP reviewed back in 2013. It has certainly been a very positive journey for the trial, the patients who participated on the trial, for the CAP to have been involved with this, and of course for ANZUP.

A big thank you to the ANZUP Chair Ian Davis and ANZUP CEO Marg McJannett who have been ever present and supportive of the CAP since our inception in 2012. It has been a very positive experience for the CAP to be part of ANZUP.

We have certainly been very busy contributing this year. Sometimes you may feel a little zoomed out but this format has really enhanced the CAP meeting experience as we would not have had all these meetings face to face without restrictions.

We continue to look forward to being able to contribute to ANZUP’s activities. The CAP is currently a great team and we all enjoy working together. So here’s to 2021 – we are well versed in taking on whatever opportunities or challenges we are faced with.

In closing we thank the ANZUP Board, the Executive team and the membership for supporting and engaging with the CAP. We look forward to 2021 being even bigger and better. Wishing you all a very safe and healthy Christmas and New Year.

BELINDA JAGO & RAY ALLEN Chair and Deputy Chair, CAP

v ANZUP CAP